Office of the Director, Notice of Charter Renewal

Issuing agencies

Full Text

<html>
<head>
<title>Federal Register, Volume 91 Issue 213 (Thursday, November 5, 2026)</title>
</head>
<body><pre>
[Federal Register Volume 91, Number 213 (Thursday, November 5, 2026)]
[Notices]
[Pages 69852-69854]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2026-22549]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Office of the Director, Notice of Charter Renewal

    In accordance with Title 41 of the U.S. Code of Federal 
Regulations, Section 102-3.65(a), notice is hereby given that the 
charter for the National Toxicology Program Advisory Committee (NTPAC) 
is being renewed for an additional two-year period on November 14, 
2026.
    It is determined that the NTPAC is in the public interest in 
connection with the performance of duties imposed on the National 
Institutes of Health by law, and that these duties can best be 
performed through the advice and counsel of this group.
    The Public Interest Determination follows:

National Institutes of Health

National Toxicology Program Advisory Committee

Public Interest Determination

    Pursuant to 41 U.S.C. 102-3.60(a), to establish, renew, 
reestablish, or merge a discretionary (agency discretion) advisory 
committee, an agency must first consult with the General Services 
Administration's Committee Management Secretariat (the Secretariat) 
and, as part of the consultation, provide a written public interest 
determination approved by the head of the agency to the Secretariat 
with a copy to the Office of Management and Budget. In addition, 
pursuant to 41 U.S.C. 102-3.35, an agency shall follow the same 
consultation process and document in writing the same determination of 
need before creating a subcommittee under a discretionary committee 
that is not made up entirely of members of a parent advisory committee.
    Information on the following factors for the committee is provided 
to the Secretariat to demonstrate that renewing the committee is in the 
public interest:

[[Page 69853]]

    1. Annual budget: The estimated annual costs for operating the 
Committee include the following:
    a. Federal personnel (based on full-time equivalent (FTE) usage 
basis) and other Federal internal costs: The estimated annual person-
years of staff support required 0.3 at an estimated cost of $56,927.
    b. Other Federal internal costs: The estimate for other Federal 
internal costs is $2,096.
    c. Proposed payments to members: The estimated payment for 12 non-
Federal members is $6,000.
    d. Proposed number of members: The Committee will consist of up to 
12 members appointed by the Secretary.
    e. Reimbursable costs: The estimate for reimbursable costs, 
including members' travel expenses, is $88,875.
    2. If applicable, the total dollar value of grants expected to be 
recommended during the fiscal year: N/A.
    3. Criteria for selecting members to ensure the committee has the 
necessary expertise and fairly balanced membership:
    The Committee will consist of up to 12 members appointed by the 
Secretary. Members will be selected from recognized authorities 
knowledgeable in and with contemporary expertise relevant to toxicology 
and the NTP mission, including but not limited to expertise relevant to 
toxicology, translational science, medicine, communication sciences, 
and data sciences. Members will be invited to serve for overlapping 
terms of up to four years. Federal employees are not eligible to be 
members of this Committee. All members must be eligible to serve as 
Special Government Employees (SGE) and will serve as SGEs, as defined 
by 18 U.S.C. 202. A member will serve after the expiration of that 
member's term until a successor has taken office. Any member appointed 
to fill a vacancy for an unexpired term will be appointed for the 
remainder of that term.
    4. List of all other Federal advisory committees of the agency:

<bullet> Advisory Committee on Research on Women's Health
<bullet> Advisory Committee to the Director, National Institutes of 
Health
<bullet> Advisory Council on Parkinson's Research, Care and Services
<bullet> Aging and Neurodegeneration Integrated Review Group
<bullet> AIDS Research Advisory Committee, NIAID
<bullet> Applied Immunology and Disease Control Integrated Review Group
<bullet> Applied Therapeutics for Cancer Integrated Review Group
<bullet> Biobehavioral and Behavioral Processes Integrated Review Group
<bullet> Bioengineering Sciences & Technologies Integrated Review Group
<bullet> Biological Chemistry and Macromolecular Biophysics Integrated 
Review Group
<bullet> Board of Regents of the National Library of Medicine
<bullet> Board of Scientific Counselors Eunice Kennedy Shriver National 
Institute of Child Health and Human Development
<bullet> Board of Scientific Counselors National Human Genome Research 
Institute
<bullet> Board of Scientific Counselors of the National Heart, Lung, 
and Blood Institute
<bullet> Board of Scientific Counselors of the NIH Clinical Center
<bullet> Board of Scientific Counselors, Division of Translational 
Toxicology
<bullet> Board of Scientific Counselors, National Cancer Institute
<bullet> Board of Scientific Counselors, National Center for 
Complementary and Integrative Health
<bullet> Board of Scientific Counselors, National Eye Institute
<bullet> Board of Scientific Counselors, National Institute of 
Arthritis and Musculoskeletal and Skin Diseases
<bullet> Board of Scientific Counselors, National Institute of 
Biomedical Imaging and Bioengineering
<bullet> Board of Scientific Counselors, National Institute of Dental 
and Craniofacial Research
<bullet> Board of Scientific Counselors, National Institute of Diabetes 
and Digestive and Kidney Diseases
<bullet> Board of Scientific Counselors, National Institute of 
Environmental Health Sciences
<bullet> Board of Scientific Counselors, National Institute of Mental 
Health
<bullet> Board of Scientific Counselors, National Institute of 
Neurological Disorders and Stroke
<bullet> Board of Scientific Counselors, National Institute on Aging
<bullet> Board of Scientific Counselors, National Institute on Alcohol 
Abuse and Alcoholism
<bullet> Board of Scientific Counselors, National Institute on Deafness 
and Other Communication Disorders
<bullet> Board of Scientific Counselors, National Institute on Drug 
Abuse
<bullet> Board of Scientific Counselors, National Institute on Minority 
Health and Health Disparities and National Institute of Nursing 
Research
<bullet> Board of Scientific Counselors, National Library of Medicine
<bullet> Brain Disorders and Clinical Neuroscience Integrated Review 
Group
<bullet> Cardiovascular and Respiratory Sciences Integrated Review 
Group
<bullet> Cell Biology Integrated Review Group
<bullet> Center for Scientific Review Special Emphasis Panel
<bullet> Council of Councils
<bullet> Cures Acceleration Network Review Board
<bullet> Digestive, Kidney and Urological Systems Integrated Review 
Group
<bullet> Division of Intramural Research Board of Scientific Counselors 
National Institute of Allergy and Infectious Diseases
<bullet> Emerging Technologies and Training Neurosciences Integrated 
Review Group
<bullet> Endocrinology, Metabolism, Nutrition and Reproductive Sciences 
Integrated Review Group
<bullet> Fogarty International Center Advisory Board
<bullet> Genes, Genomes, and Genetics Integrated Review Group
<bullet> Healthcare Delivery and Methodologies Integrated Review Group
<bullet> Infectious Diseases and Immunology A Integrated Review Group
<bullet> Infectious Diseases and Immunology B Integrated Review Group
<bullet> Integrative, Functional and Cognitive Neuroscience Integrated 
Review Group
<bullet> Interagency Autism Coordinating Committee
<bullet> Interagency Pain Research Coordinating Committee
<bullet> Interdisciplinary Molecular Sciences and Training Integrated 
Review Group
<bullet> Molecular, Cellular and Developmental Neuroscience Integrated 
Review Group
<bullet> Muscular Dystrophy Coordinating Committee
<bullet> Musculoskeletal, Oral, and Skin Sciences Integrated Review 
Group
<bullet> National Advisory Allergy and Infectious Diseases Council
<bullet> National Advisory Board on Medical Rehabilitation Research
<bullet> National Advisory Child Health and Human Development Council
<bullet> National Advisory Council for Biomedical Imaging and 
Bioengineering
<bullet> National Advisory Council for Complementary and Integrative 
Health
<bullet> National Advisory Council for Human Genome Research
<bullet> National Advisory Council for Nursing Research
<bullet> National Advisory Council on Aging
<bullet> National Advisory Council on Alcohol Abuse and Alcoholism
<bullet> National Advisory Council on Drug Abuse
<bullet> National Advisory Council on Minority Health and Health 
Disparities

[[Page 69854]]

<bullet> National Advisory Dental and Craniofacial Research Council
<bullet> National Advisory Environmental Health Sciences Council
<bullet> National Advisory Eye Council
<bullet> National Advisory General Medical Sciences Council
<bullet> National Advisory Mental Health Council
<bullet> National Advisory Neurological Disorders and Stroke Council
<bullet> National Arthritis and Musculoskeletal and Skin Diseases 
Advisory Council
<bullet> National Cancer Advisory Board
<bullet> National Cancer Institute Clinical Trials and Translational 
Research Advisory Committee
<bullet> National Cancer Institute Council of Research Advocates
<bullet> National Center for Advancing Translational Sciences Advisory 
Council
<bullet> National Deafness and Other Communication Disorders Advisory 
Council
<bullet> National Diabetes and Digestive and Kidney Diseases Advisory 
Council
<bullet> National Heart, Lung, and Blood Advisory Council
<bullet> National Science Advisory Board for Biosecurity
<bullet> National Toxicology Program Advisory Committee
<bullet> National Toxicology Program Special Emphasis Panel
<bullet> NIH Clinical Center Research Hospital Board
<bullet> Office of AIDS Research Advisory Council
<bullet> Office of Research Infrastructure Programs Special Emphasis 
Panel
<bullet> Oncology 1--Basic Translational Integrated Review Group
<bullet> Oncology 2--Translational Clinical Integrated Review Group
<bullet> Population Sciences and Epidemiology Integrated Review Group
<bullet> President's Cancer Panel
<bullet> Risk, Prevention and Health Behavior Integrated Review Group
<bullet> Scientific Advisory Committee on Alternative Toxicological 
Methods
<bullet> Scientific and Technical Review Board on Biomedical and 
Behavioral Research Facilities
<bullet> Scientific Management Review Board
<bullet> Sickle Cell Disease Advisory Committee
<bullet> Sleep Disorders Research Advisory Board
<bullet> Social and Community Influences on Health Integrated Review 
Group
<bullet> Surgical Sciences, Biomedical Imaging and Bioengineering 
Integrated Review Group
<bullet> Vaccine Research Center Board of Scientific Counselors 
National Institute of Allergy and Infectious Diseases
<bullet> Vascular and Hematology Integrated Review Group

    5. Justification that the information or advice provided by the 
Federal advisory committee or subcommittee is not available from 
another Federal advisory committee, another Federal Government source, 
or any other more cost-effective and less burdensome source:
    The committee is a technical advisory group established to provide 
guidance to the National Toxicology Program Steering Committee and 
Program Director on issues related to the program's scientific content. 
The Committee also evaluates the scientific quality of the NTP's 
interagency and collaborative efforts. Members will be selected from 
recognized authorities knowledgeable in and with contemporary expertise 
relevant to toxicology and the NTP mission, including but not limited 
to expertise in toxicology, translational science, medicine, 
communication sciences, and data sciences.
    6. If the consultation is a committee renewal, a summary of the 
previous accomplishments of the committee and the reasons it needs to 
continue:
    The Board provides advice to the National Toxicology Program 
Steering Committee and Program Director on matters of scientific 
program content, to evaluate the scientific merits of the interagency 
and collaborative programs of the NTP, and to provide external 
scientific advice on NTP activities. Due to the unique function and 
objectives of the NTP within the public sector, an independent advisory 
committee is required that includes a breadth of scientific expertise 
within the membership and a membership that can evaluate and advise on 
activities ranging from basic research to large-scale chemical testing.
    When the committee last met, they focused on recommendations to 
advance strategic priorities, program evaluation, stakeholder 
engagement, climate change impacts, and social determinants of health. 
They had extensive discussions that resulted in numerous 
recommendations to strengthen toxicology assessment approaches, improve 
performance metrics, expand scientific partnerships, and address 
vulnerable population exposures. This included a unanimous 
recommendation for approval of a bioinformatics support contract 
concept to enhance NIEHS research capabilities involving complex 
multidimensional datasets.
    7. Explanation of why the committee/subcommittee is essential to 
the conduct of agency business:
    Due to the unique function and objectives of the NTP within the 
public sector, an independent advisory committee is required that 
includes a breadth of scientific expertise within the membership and a 
membership that can evaluate and advise on activities ranging from 
basic research to large-scale chemical testing.
    In conclusion, this public interest determination documents that 
renewing the committee is in the public interest, essential to the 
conduct of agency business, and that the information to be obtained is 
not already available through another advisory committee or source 
within the Federal Government.
    Inquiries may be directed to Patricia Brandt Hansberger, Acting 
Director, Office of Federal Advisory Committee Policy, Office of the 
Director, National Institutes of Health, 6701 Democracy Boulevard, 
Suite 1000, Bethesda, Maryland 20892 (Mail code 4875), Telephone (301) 
496-2123, or <a href="/cdn-cgi/l/email-protection#9dedfce9eff4fef4fcb3f5fcf3eefff8effaf8efddf3f4f5b3faf2eb"><span class="__cf_email__" data-cfemail="8bfbeafff9e2e8e2eaa5e3eae5f8e9eef9eceef9cbe5e2e3a5ece4fd">[email&#160;protected]</span></a>.

    Dated: October 28, 2026.
Denise M. Santeufemio,
Supervisory Program Analyst, Office of Federal Advisory Committee 
Policy.
[FR Doc. 2026-22549 Filed 11-4-26; 8:45 am]
BILLING CODE 4167-05-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>